Search





Search





Markets
/
Stocks
/
nasdaq-avtx
/

Avalo Therapeutics Inc

AVTX

Add to Watchlist

17.740USD

-1.270-6.68%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

932.51MMarket Cap

LossP/E TTM



Avalo Therapeutics Inc

17.740

-1.270-6.68%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Avalo Therapeutics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Avalo Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 80 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 47.80.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Avalo Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

80 / 382

Overall Ranking

197 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Avalo Therapeutics Inc Highlights

StrengthsRisks

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).

Growing

The company is in a growing phase, with the latest annual income totaling USD 59.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 59.00K.

Undervalued

The company’s latest PE is -3.19, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 24.87M shares, increasing 21.84% quarter-over-quarter.

Held by Steven Cohen

Star Investor Steven Cohen holds 627.50K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 6.09.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

47.800

Target Price

+151.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of Avalo Therapeutics Inc is 6.70, ranking 209 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.70

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.06

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Avalo Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of Avalo Therapeutics Inc is 7.46, ranking 113 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.19, which is -144.35% below the recent high of 1.41 and -22.86% above the recent low of -3.92.

Score

Industry at a Glance

Previous score

7.46

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 80/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of Avalo Therapeutics Inc is 8.83, ranking 51 out of 382 in the Biotechnology & Medical Research industry. The average price target is 35.00, with a high of 48.00 and a low of 24.00.

Score

Industry at a Glance

Previous score

8.83

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

47.800

Target Price

+151.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Avalo Therapeutics Inc

AVTX

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of Avalo Therapeutics Inc is 6.48, ranking 236 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 23.84 and the support level at 12.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.61

Change

-0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.483

Buy

RSI(14)

53.078

Neutral

STOCH(KDJ)(9,3,3)

47.478

Sell

ATR(14)

2.019

Low Volatility

CCI(14)

9.436

Neutral

Williams %R

55.527

Sell

TRIX(12,20)

1.533

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

19.358

Sell

MA10

19.308

Sell

MA20

16.640

Buy

MA50

15.673

Buy

MA100

15.946

Buy

MA200

14.886

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Avalo Therapeutics Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 60.06%, representing a quarter-over-quarter increase of 20.42%. The largest institutional shareholder is Steven Cohen, holding a total of 627.50K shares, representing 1.52% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

2.13M

+864.97%

BVF Partners L.P.

1.36M

+0.00%

Nantahala Capital Management, LLC

1.24M

OrbiMed Advisors, LLC

1.19M

-12.01%

UBS Financial Services, Inc.

477.82K

+956.93%

Affinity Asset Advisors LLC

1.05M

Millennium Management LLC

934.43K

+3.16%

Caligan Partners, LP

881.53K

+5.78%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Avalo Therapeutics Inc is 3.83, ranking 112 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.86. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.